Umecrine Cognition
Solna
About Umecrine Cognition
Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders caused by endogenous CNS-active steroids (GABA steroids). Its primary focus is on addressing the neurocognitive signs and symptoms associated with hepatic encephalopathy. By targeting the underlying biochemical mechanisms, the company aims to enable healthcare providers to offer more precise and effective therapies for patients affected by this serious liver-related neurological condition.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Last round: Convertible Note (Jul 2025)
- Website: umecrinecognition.com
- Phone: +46 8 52 48 44 82
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/umecrine-cognition-22551 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.